Efficacy of continuing medical education to reduce the risk of buprenorphine diversion

Journal of Substance Abuse Treatment

Volumn 41, Issue 3, 2011, Pages 321-329

  Lofwall, Michelle R ^a   Wunsch, Martha J ^a   Nuzzo, Paul A ^a   Walsh, Sharon L ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Buprenorphine; Continuing medical education; Diversion and misuse; Office based opioid dependence treatment

Indexed keywords

BUPRENORPHINE;

ARTICLE; CLINICAL PRACTICE; CONTINUING MEDICAL EDUCATION; DRUG MISUSE; HEALTH SURVEY; HUMAN; MEDICAL EDUCATION; PHYSICIAN ATTITUDE; PRIORITY JOURNAL;

BEHAVIOR, ADDICTIVE; BUPRENORPHINE; DRUG ADMINISTRATION SCHEDULE; EDUCATION, MEDICAL, CONTINUING; HUMANS; LONGITUDINAL STUDIES; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 80052319681     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2011.04.008     Document Type: Article

References (31)

1. Amass L., Bickel W.K., et al. Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacology (Berl) 1998, 136:217-225.
2. Centers for Disease Control and Prevention Overdose deaths involving prescription opioids among Medicaid enrollees-Washington, 2004-2007. MMWR Morb Mortal Wkly Rep 2009, 58:1171-1175.
3. Cicero T.J., Surratt H., et al. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States. Pharmacoepidemiol Drug Saf 2007, 16:827-840.
4. Cicero T.J., Surratt H.L., et al. Use and misuse of buprenorphine in the management of opioid addiction. J Opioid Manag 2007, 3:302-308.
5. CSAT Report of the Center for Substance Abuse Work Group Federation of State Medial Boards of the United States. Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office Available at. http://www.buprenorphine.samhsa.gov/model.html.
6. Dasgupta N., Bailey E.J., et al. Post-marketing surveillance of methadone and buprenorphine in the United States. Pain Med 2010, 11:1078-1091.
7. Fiellin D.A., Kleber H., et al. Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat 2004, 27:153-159.
8. Galanter M. Network therapy. The American psychiatric publishing textbook of substance abuse treatment 2008, 401-412. American Psychiatric Publishing, Inc, Washinton, DC. M. Galanter, H. Kleber (Eds.).
9. Galanter M., Dermatis H., et al. Network therapy for cocaine abuse: Use of family and peer supports. Am J Addict 2002, 11:161-166.
10. Galanter M., Dermatis H., et al. Network therapy: Decreased secondary opioid use during buprenorphine maintenance. J Subst Abuse Treat 2004, 26:313-318.
11. Greenwald M.K., Johanson C.E., et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 2003, 28:2000-2009.
12. Higgins S.T., Silverman K. Contingency management. The American psychiatric publishing textbook of substance abuse treatment 2008, 387-400. American Psychiatric Press, Washington, DC. M.G. Galanter, H.D. Kleber (Eds.).
13. Johnson R.E., Chutuape M.A., et al. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000, 343:1290-1297.
14. Johnson R.E., Strain E.C., et al. Buprenorphine: How to use it right. Drug Alcohol Depend 2003, 70:S59-S77.
15. Lofwall M.R., Walsh S.L. Clinical challenges managing buprenorphine diversion. Journal of Addiciton Medicine 2010, 4:243.
16. Lofwall M.R., Wunsch M.J., et al. Pharmacy willingness to partner with office-based opioid dependence treatment providers in conducting random buprenorphine pill counts. Am J Addict 2010, 19:195-196.
17. McCance-Katz, E. F. (2008). "Emerging clincal challenges in prescribing buprenorphine available online ". http://buprenorphine.samhsa.gov/presentations.html.
18. McLellan A.T., Arndt I.O., et al. The effects of psychosocial services in substance abuse treatment. Jama 1993, 269:1953-1959.
19. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. A treatment improvement protocol TIP 40 2004, 1-171. Dept. of Health and Human Services Publication No. (SMA) 04-3939. Substance Abuse and Mental Health Services Administration, Rockville, MD. L. McNicholas (Ed.).
20. Monte A.A., Mandell T., et al. Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence. J Addict Dis 2009, 28:226-231.
21. O'Brien C.P., O'Brien T.J., et al. Conditioning of narcotic abstinence symptoms in human subjects. Drug Alcohol Depend 1975, 1:115-123.
22. Paulozzi L.J., Budnitz D.S., et al. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf 2006, 15:618-627.
23. Paulozzi L.J., Ryan G.W. Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med 2006, 31:506-511.
24. Reckitt Benckiser Pharmaceuticals Inc. (2009). Medical advisory and best-practices update.
25. SAMHSA Office of Applied Studies, National Survey on Drug Use and Health, Detailed tables 6.47 and 6.48 accessed December 15, 2010 @ http://oas.samhsa.gov/NSDUH/2k9NSDUH/tabs/Sect6peTabs1to54.htm#Tab6.48A.
26. SAMHSA Physician clinical support system clinical guidances available on-line @ http://pcssb.org/educational-and-training-resources/clinical-guidances/.
27. Schottenfeld R.S., Pakes J., et al. Thrice-weekly versus daily buprenorphine maintenance. Biol Psychiatry 2000, 47:1072-1079.
28. Strain E.C., Lofwall M.R. Buprenorphine maintenance. The American psychiatric publishing textbook of substance abuse treatment 2008, 309-324. American Psychiatric Publishing, Washington, DC. M.G. Galanter, H.D. Kleber (Eds.).
29. Walsh S.L., Preston K.L., et al. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clin Pharmacol Ther 1994, 55:569-580.
30. Walsh S.L., Preston K.L., et al. Acute administration of buprenorphine in humans: Partial agonist and blockade effects. J Pharmacol Exp Ther 1995, 274:361-372.
31. Wunsch M.J., Nakamoto K., et al. Opioid deaths in rural Virginia: A description of the high prevalence of accidental fatalities involving prescribed medications. Am J Addict 2009, 18:5-14.